Ideas to lND - Your Pathway to Discovery
Empowering Preclinical Innovation
Unlock the full potential of your preclinical research with Cyagen Biosciences. Our integrated solutions span from custom cell and animal model development through preclinical experiments, ensuring every phase of your project is expertly handled. Discover how we can help transform your innovative ideas into actionable outcomes and help translate your research discoveries into INDs.
CTGA Grant
Receive up to $1M in Funding for Custom Model Generation
Explore
Innovative Solutions & Trusted Products
Special Promotions & Discounts
See All Promotions
Free Trial
Experience Next-Level Humanized Research — Try NKG Mice for Free
Cyagen is inviting researchers in the US and EU to evaluate our NKG mice at no cost. This limited-time offer supports preclinical studies and fosters collaboration within the biomedical research community.
Explore
Special Deal
Research Now, Pay Later: Flexible Funding for Custom Animal Models
We understand that funding delays shouldn’t slow down scientific progress. Our GrantBridge provides flexible payment options to ensure that you can secure your critical research resources now while aligning payment with your funding schedule.
Explore
Price Match
Price Match + 5% Off Custom Cell Models
Cyagen guarantees the best-value solution for your custom cell model (CCM) project with our Competitor Quote Price Match plus 5% discount offer—just submit any competitor’s quote to receive a free expert evaluation and enjoy cost savings without compromising quality.
Explore
Your Partners in Preclinical Progress
19
Years of Genetic Innovation
7,000
Global Bioscience Partners
50,000
Mouse & Rat Models Delivered
10,925
SCI Journal Citations
250,000
SPF Animals in AAALAC-Accredited Facilities
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Resource Library
BLOG & INSIGHTS
More Insights
Beyond Aβ: A New Era of Alzheimer's Disease Research and the Power of Tau Humanized Models
Alzheimer's disease (AD) remains one of the greatest challenges in modern medicine. While research has long centered on amyloid-beta (Aβ), recent clinical results highlight the need for broader strategies. Attention is now shifting to Tau protein, and Cyagen’s advanced humanized mouse models are providing the tools to drive the next generation of AD therapies.
August 28, 2025
Schedule Meeting
UPCOMING EVENT
More
The 30th Annual Conference of CLSS-UK
Cyagen will be attending the 30th Annual Conference of the Chinese Life Scientists Society in Cambridge, UK. Visit our booth to explore various custom mouse models and comprehensive CRO services
Schedule Meeting
WEBINAR
More
Humanized Tauopathy in HUGO Mouse Models: Indication for Advanced AD Pre-Clinical Studies
This webinar will showcase Cyagen’s advanced humanized mouse models for Alzheimer’s disease and other neurodegenerative conditions. We will highlight hTAU strains and HUGO technology, presenting validation data and applications that enable more relevant and robust preclinical research.
Schedule Meeting